The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,012.00
Bid: 2,000.00
Ask: 2,004.00
Change: 18.00 (0.90%)
Spread: 4.00 (0.20%)
Open: 1,991.00
High: 2,012.00
Low: 1,969.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

5 Feb 2024 08:46

RNS Number : 0216C
Hikma Pharmaceuticals Plc
05 February 2024

Notice of preliminary results

London, 5 February 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its preliminary financial results for the year ended 31 December 2023 on Thursday 22 February 2024.

A recording of the 2023 Preliminary Results presentation and slide deck will be available on the Group's website at www.hikma.com from 7:00am GMT. Hikma will also hold a Q&A call for analysts at 12:00pm GMT, and a recording will be made available on the Company's website.

To join the call please, please register your attendance in advance by clicking here.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 (0)7776 477050

Guy Featherstone

Associate Director, Investor Relations

+44 (0)20 3892 4389/ +44 (0)7795 896738

Layan Kalisse

Senior Associate, Investor Relations

+44 (0)20 7399 2788/ +44 (0)7970 709912

Teneo (Press):

Charles Armitstead / Rob Yates +44 (0)7703 330 269/ +44 (0)7715 375443

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORDZGGZRKKGDZG
Date   Source Headline
6th May 20225:54 pmRNSTransaction in Own Shares
5th May 20225:47 pmRNSTransaction in Own Shares
5th May 20227:00 amRNSHikma updates Generics guidance for 2022
4th May 20225:58 pmRNSTransaction in Own Shares
3rd May 20226:08 pmRNSTransaction in Own Shares
29th Apr 20225:29 pmRNSTransaction in Own Shares
29th Apr 20225:05 pmRNSCorrection statement re Opiant
29th Apr 20227:15 amRNSTrading Statement
28th Apr 20226:05 pmRNSTransaction in Own Shares
27th Apr 20226:17 pmRNSTransaction in Own Shares
27th Apr 20227:00 amRNSTransaction in Own Shares
25th Apr 20226:04 pmRNSTransaction in Own Shares
25th Apr 20223:42 pmRNSResult of AGM
25th Apr 20227:00 amRNSNotice of GM
22nd Apr 20226:15 pmRNSTransaction in Own Shares
21st Apr 20226:06 pmRNSTransaction in Own Shares
21st Apr 20222:15 pmRNSAcquisition
20th Apr 20225:59 pmRNSTransaction in Own Shares
20th Apr 20227:00 amRNSFTC preliminary approval for Custopharm
19th Apr 20225:49 pmRNSTransaction in Own Shares
14th Apr 20225:35 pmRNSTransaction in Own Shares
13th Apr 20225:19 pmRNSTransaction in Own Shares
12th Apr 20225:55 pmRNSTransaction in Own Shares
12th Apr 20225:49 pmRNSDirector/PDMR Shareholding
11th Apr 20226:09 pmRNSTransaction in Own Shares
11th Apr 20227:00 amRNSShare Buyback Programme
8th Apr 20225:16 pmRNSTransaction in Own Shares
7th Apr 20225:53 pmRNSTransaction in Own Shares
5th Apr 20225:59 pmRNSTransaction in Own Shares
4th Apr 20226:09 pmRNSTransaction in Own Shares
1st Apr 20226:13 pmRNSTransaction in Own Shares
1st Apr 20225:46 pmRNSBlock listing Interim Review
31st Mar 20226:09 pmRNSTransaction in Own Shares
30th Mar 20225:57 pmRNSTransaction in Own Shares
30th Mar 202212:54 pmRNSTransaction in Own Shares
28th Mar 20226:09 pmRNSTransaction in Own Shares
25th Mar 20225:55 pmRNSTransaction in Own Shares
24th Mar 20226:03 pmRNSTransaction in Own Shares
23rd Mar 20225:08 pmRNSTransaction in Own Shares
22nd Mar 20226:03 pmRNSTransaction in Own Shares
21st Mar 20225:58 pmRNSTransaction in Own Shares
18th Mar 20226:32 pmRNSTransaction in Own Shares
17th Mar 20226:03 pmRNSTransaction in Own Shares
17th Mar 202210:00 amRNSAnnual Financial Report
16th Mar 20225:48 pmRNSTransaction in Own Shares
15th Mar 20225:51 pmRNSTransaction in Own Shares
15th Mar 202210:58 amRNSDirector/PDMR Shareholding
14th Mar 20226:23 pmRNSTransaction in Own Shares
11th Mar 20226:11 pmRNSTransaction in Own Shares
10th Mar 20225:48 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.